CD19 and neoplasm: As shown, dual-targeted CAR-T cells exerted cytotoxicity against CD19+/HER2+ tumor cells, but spared PD-L1+ normal cells in the context of either CD19 (Additional file 4: Figure S4c-d) or HER2 CAR (Fig. 5c-d).